FarmaMondo approves Normokineztine in Russian Federation for Huntington disease patients. The product, license to FarmaMondo from AOP Orphan, has been approved as the sole indicated therapy currently available for Russian patients suffering from the indicated disease. FarmaMondo will launch the product in H1 2016 through a dedicated campaign with relevant KOL.
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Powered by 